Discovery of N -substituted-2-oxoindolin benzoylhydrazines as c-MET/SMO modulators in EGFRi-resistant non-small cell lung cancer

• Published in: RSC medicinal chemistry 2024-10
• Main Authors: Tomassi, Stefano, Natale, Benito, Roggia, Michele, Amato, Luisa, De Rosa, Caterina, Della Corte, Carminia Maria, Baglini, Emma, Amendola, Giorgio, Messere, Anna, Di Maro, Salvatore, Barresi, Elisabetta, Da Settimo, Federico, Trincavelli, Maria Letizia, Ciardiello, Fortunato, Taliani, Sabrina, Morgillo, Floriana, Cosconati, Sandro
• Format: Article
• Language: English
• Subjects: Chemistry
• ISSN: 2632-8682; 2632-8682
• DOI: 10.1039/d4md00553h

Non-small cell lung cancer (NSCLC), the leading cause of cancer-related mortality worldwide, poses a formidable challenge due to its heterogeneity and the emergence of resistance to targeted therapies. While initially effective, first- and third-generation EGFR-tyrosine kinase inhibitors (TKIs) often fail to control disease progression, leaving patients with limited treatment options. To address this unmet medical need, we explored the therapeutic potential of multitargeting agents that simultaneously inhibit two key signalling pathways, the mesenchymal-epithelial transition factor (c-MET) and the G protein-coupled receptor Smoothened (SMO), frequently dysregulated in NSCLC. By employing a combination of drug repurposing and structure-based structure-activity relationship (SAR) studies, we identified and developed novel c-MET/SMO-targeting agents with antiproliferative activity against first- as well as third-generation EGFR-TKI-resistant NSCLC cells suggesting a synergistic effect arising from the simultaneous inhibition of c-MET and SMO.